NASDAQ:INMB INmune Bio (INMB) Stock Price, News & Analysis → Hurry! Buy this stock before the Robinhood traders do! (From Traders Agency) (Ad) Free INMB Stock Alerts $8.76 -0.19 (-2.12%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$8.67▼$9.1150-Day Range$8.37▼$11.8452-Week Range$6.50▼$14.74Volume68,500 shsAverage Volume103,065 shsMarket Capitalization$173.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get INmune Bio alerts: Email Address Ad Wealthpin ProTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house republicans called “The Key To America’s Economic Future”.You just have to make this simple move before July 30, 2024. About INmune Bio Stock (NASDAQ:INMB)INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Read More INMB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INMB Stock News HeadlinesJune 3, 2024 | americanbankingnews.comINmune Bio, Inc. (NASDAQ:INMB) Sees Significant Increase in Short InterestMay 30, 2024 | globenewswire.comINmune Bio Inc. to Join Russell 3000® IndexMay 13, 2024 | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call TranscriptMay 12, 2024 | finance.yahoo.comINmune Bio First Quarter 2024 Earnings: EPS Misses ExpectationsMay 11, 2024 | markets.businessinsider.comRobust Pipeline and Financial Stability Underpin Buy Rating for Inmune BioMay 10, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateMay 9, 2024 | globenewswire.comINmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateMay 7, 2024 | finance.yahoo.comINmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9May 1, 2024 | msn.comINmune Bio files for $250M mixed shelf offeringApril 30, 2024 | finance.yahoo.comINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsApril 30, 2024 | globenewswire.comINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsApril 29, 2024 | globenewswire.comINmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate CancerApril 26, 2024 | finance.yahoo.comINmune Bio Independent Director Acquires 80% More StockApril 25, 2024 | markets.businessinsider.comInmune Bio Earns Buy Rating on Positive XPro Developments and Strong FinancialsApril 25, 2024 | globenewswire.comINmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 23, 2024 | globenewswire.comINmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayApril 22, 2024 | msn.comINmune Bio rises 2%, on $4.5M direct offeringApril 22, 2024 | finance.yahoo.comINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingApril 22, 2024 | globenewswire.comINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingApril 8, 2024 | finance.yahoo.comINmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024April 8, 2024 | globenewswire.comINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)April 1, 2024 | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | finance.yahoo.comINmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 30, 2024 | seekingalpha.comINmune Bio, Inc. (INMB) Q4 2023 Earnings Call TranscriptSee More Headlines Receive INMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/10/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INMB CUSIPN/A CIK1711754 Webwww.inmunebio.com Phone(858) 964-3720FaxN/AEmployees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,010,000.00 Net Margins-26,333.59% Pretax Margin-26,333.58% Return on Equity-86.16% Return on Assets-58.41% Debt Debt-to-Equity RatioN/A Current Ratio1.71 Quick Ratio1.71 Sales & Book Value Annual Sales$160,000.00 Price / Sales1,082.96 Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book4.23Miscellaneous Outstanding Shares19,780,000Free Float12,819,000Market Cap$173.27 million OptionableOptionable Beta1.89 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Raymond Joseph Tesi M.D. (Age 68)Co-Founder, President, CEO, Chief Medical Officer & Chairman Comp: $500.5kMr. David J. Moss M.B.A. (Age 54)CFO, Treasurer & Secretary Comp: $394.9kDr. Mark William Lowdell BSc (Age 61)FRCPath, MICR, MSc, Ph.D., Chief Scientific Officer & Chief Manufacturing Officer Comp: $150.24kMr. Joshua S. Schoonover Esq.General CounselKey CompetitorsX4 PharmaceuticalsNASDAQ:XFORCidara TherapeuticsNASDAQ:CDTXFortress BiotechNASDAQ:FBIOApplied Genetic TechnologiesNASDAQ:AGTCREGENXBIONASDAQ:RGNXView All CompetitorsInsiders & InstitutionsJanney Montgomery Scott LLCSold 22,648 shares on 5/1/2024Ownership: 0.774%Westside Investment Management Inc.Sold 7,475 shares on 4/19/2024Ownership: 0.189%Fermata Advisors LLCBought 2,025 shares on 4/12/2024Ownership: 0.174%Scott JudaBought 7,000 shares on 11/10/2023Total: $48,650.00 ($6.95/share)Timothy J SchroederSold 10,000 sharesTotal: $110,100.00 ($11.01/share)View All Insider TransactionsView All Institutional Transactions INMB Stock Analysis - Frequently Asked Questions How have INMB shares performed in 2024? INmune Bio's stock was trading at $11.26 at the beginning of 2024. Since then, INMB shares have decreased by 22.2% and is now trading at $8.76. View the best growth stocks for 2024 here. Are investors shorting INmune Bio? INmune Bio saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 1,920,000 shares, an increase of 11.0% from the April 30th total of 1,730,000 shares. Based on an average daily volume of 116,400 shares, the short-interest ratio is currently 16.5 days. Currently, 14.7% of the company's shares are short sold. View INmune Bio's Short Interest. When is INmune Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our INMB earnings forecast. How were INmune Bio's earnings last quarter? INmune Bio, Inc. (NASDAQ:INMB) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.61) earnings per share for the quarter. The company had revenue of $0.01 million for the quarter. INmune Bio had a negative trailing twelve-month return on equity of 86.16% and a negative net margin of 26,333.59%. What other stocks do shareholders of INmune Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX). Who are INmune Bio's major shareholders? INmune Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Janney Montgomery Scott LLC (0.77%), Westside Investment Management Inc. (0.19%) and Fermata Advisors LLC (0.17%). Insiders that own company stock include David J Moss, Mark William Lowdell, Raymond Joseph Tesi, Scott Juda and Timothy J Schroeder. View institutional ownership trends. How do I buy shares of INmune Bio? Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INMB) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.